[Courtesy of Chong Kun Dang]
SEOUL -- CKD-11101, a biosimilar developed by South Korea's pharmaceutical company Chong Kun Dang has won regulatory approval at home to sell the world's first copycat of Nesp for the treatment of anemia of chronic disease associated with cancer.
Chong Kun Dang said the Ministry of Food and Drug Safety has approved CKD-11101. Marketing is possible in South Korea next year. It is the world's first biosimilar referencing Nesp codeveloped by Japan’s Kyowa Hakko Kirin and Amgen.
Through a partnership with a multinational company, Chong Kun Dang's biosimilar has filed for approval in Japan. The company has patented CKD-11101 in Europe and the United States to accelerate global sales.
-
- Lim Chang-won Reporter
- email : cwlim34@ajunews.com
